August 3, 2021Open Access

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

Key Points

Key points are not available for this paper at this time.

Abstract

As the demand for CAR T cell cancer therapy increases, several closed and automated production platforms are being deployed, and others are in development.This review provides a critical appraisal of these technologies that can be leveraged to scale and optimize the production of next generation CAR T cells.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Abou‐El‐Enein et al. (Tue,) studied this question.

synapsesocial.com/papers/69db24591e19c8ae08836b52 https://doi.org/https://doi.org/10.1158/2643-3230.bcd-21-0084

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs2013 · 85 citations
2A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency2003 · 1,851 citations
3Chimeric Antigen Receptor Therapy2018 · 2,296 citations
4Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies2015 · 597 citations
5B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells2011 · 1,446 citations

AI से पूछें

Bookmark

View Full Paper